Results 191 to 200 of about 1,252,753 (304)

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Dual roles of renal tubular mitochondrial Akt1 in protecting against diabetic nephropathy and improving body glucose metabolism. [PDF]

J Endocrinol
Salem ESB, Ta A, Bloom-Saldana E, Fueger PT, Wang PH.   +4 more
europepmc   +1 more source

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan‐Chia Yang, Chih‐Wei Huang, Min‐Huei Hsu, Jason C. Hsu, Chien‐Tien Su, Phung‐Anh Nguyen   +10 more
wiley   +1 more source

Type 2 diabetes mellitus exacerbates vaginal group B <i>Streptococcus</i> colonization via impaired mucosal cytokine response. [PDF]

mSphere
Robertson CM, Mercado-Evans V, Larson AB, Branthoover H, Ottinger S, Mejia ME, Hameed ZA, Gonzalez LA, Serchejian C, Ogilvie L, Zulk JJ, Patras KA.   +11 more
europepmc   +1 more source

Economic evaluations of antiobesity medications: A systematic literature review

British Journal of Clinical Pharmacology, EarlyView.
The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković, Almir Fajkić, Andrea Katrin Faour, Mirna Momčilović, Petra Turčić, Andrej Belančić   +5 more
wiley   +1 more source

Saving the Capillaries: FGFR1/KLB and MFG-E8 in Diabetic Hearts. [PDF]

Circ Res
Elbatreek MH, Lefer DJ.
europepmc   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin   +11 more
wiley   +1 more source

Hyperglycemia associated brain dysfunction: rodent models for studying diabetic cognitive deficits. [PDF]

Metab Brain Dis
Balsamo BM, Brager DH.
europepmc   +1 more source

The diabetic diet [PDF]

Diabetologia, 1983
openaire   +1 more source

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

British Journal of Clinical Pharmacology, EarlyView.
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu, Amina Haggag, Laurie Butcher, Haihui Liu, Wen Chen, Xuefeng Sun, Aruni Jha, Hongtao Yu, Anis Khan, Victoria E. R. Parker, Christer Tannergren, Xiaoliang Pan, Jianfeng Xu, Jingye Zhou   +13 more
wiley   +1 more source